Novavax, Inc (NASDAQ: NVAX) kicked off on Friday, down -10.29% from the previous trading day, before settling in for the closing price of $6.66. Over the past 52 weeks, NVAX has traded in a range of $4.43-$23.86.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 516.28% annually for the last half of the decade. While this was happening, its average annual earnings per share was recorded 212.54%. With a float of $147.60 million, this company’s outstanding shares have now reached $161.96 million.
In an organization with 952 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 73.3%, operating margin of -35.6%, and the pretax margin is -25.89%.
Novavax, Inc (NVAX) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Novavax, Inc is 8.87%, while institutional ownership is 58.80%. The most recent insider transaction that took place on Apr 14 ’25, was worth 24,406. Before that another transaction happened on Dec 13 ’24, when Company’s Director sold 4,150 for $9.02, making the entire transaction worth $37,435. This insider now owns 14,770 shares in total.
Novavax, Inc (NVAX) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 212.54% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 37.20% during the next five years compared to 25.88% growth over the previous five years of trading.
Novavax, Inc (NASDAQ: NVAX) Trading Performance Indicators
Take a look at Novavax, Inc’s (NVAX) current performance indicators. Last quarter, stock had a quick ratio of 2.03. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.77.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 2.65, a number that is poised to hit -0.05 in the next quarter and is forecasted to reach 0.38 in one year’s time.
Technical Analysis of Novavax, Inc (NVAX)
Let’s dig in a bit further. During the last 5-days, its volume was 15.21 million. That was better than the volume of 5.69 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 22.93%. Additionally, its Average True Range was 0.63.
During the past 100 days, Novavax, Inc’s (NVAX) raw stochastic average was set at 14.76%, which indicates a significant increase from 8.71% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 113.15% in the past 14 days, which was higher than the 87.19% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $6.96, while its 200-day Moving Average is $9.48. However, in the short run, Novavax, Inc’s stock first resistance to watch stands at $6.48. Second resistance stands at $6.98. The third major resistance level sits at $7.32. If the price goes on to break the first support level at $5.64, it is likely to go to the next support level at $5.30. Assuming the price breaks the second support level, the third support level stands at $4.80.
Novavax, Inc (NASDAQ: NVAX) Key Stats
The company with the Market Capitalisation of 967.77 million has total of 160,844K Shares Outstanding. Its annual sales at the moment are 682,160 K in contrast with the sum of -187,500 K annual income. Company’s last quarter sales were recorded 88,310 K and last quarter income was -81,030 K.
